Warm saline vs room temperature saline
Adverse events and complications · women undergoing outpatient hysteroscopy
1 finding from 1 review
- no estimate extracted1 study · 100 participantsGRADE not reported
Findings
What do systematic reviews say?
2,908 questions · 3,101 findings · 509 reviews
No studies found 571 · 18.4%GRADE not reported 358 · 11.5%Very low 723 · 23.3%Low 854 · 27.5%Moderate 489 · 15.8%High 106 · 3.4%
Warm saline vs room temperature saline
Quality of hysteroscopic view · women undergoing outpatient hysteroscopy
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Warm saline vs room temperature saline
Duration of the procedureassessed in seconds · women undergoing outpatient hysteroscopy
1 finding from 1 review
- no estimate extracted2 studies · 141 participantsLow
Slow vs fast subcutaneous heparin injection
Bruise size 48 hours after injection (mm/mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes onlyno estimate extracted5 studies · 503 participantsVery low
Slow vs fast subcutaneous heparin injection
Bruise size ‐ 60 hours after injection (mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 84 participantsLow
Slow vs fast subcutaneous heparin injection
Bruise size ‐ 72 hours after injection (mm2) · patients treated with subcutaneous heparin injections
1 finding from 1 review
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 140 participantsLow
Slow vs fast subcutaneous heparin injection
Bruise incidence ‐ 48 hours after injection · patients treated with subcutaneous heparin injections
Slow may leads to lower bruise incidence ‐ 48 hours after injection compared with fast subcutaneous heparin injection (low certainty).
2 findings from 1 review
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes onlyOR 0.39 [0.26, 0.6]3 studies · 444 participantsLow
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity 2021 · Cochrane Headline outcomes onlyOR 0.25 [0.1, 0.65]2 studies · 84 participantsLow
Angiotensin‐converting enzyme inhibitors vs placebo
Urinary protein or albumin excretion ‐ total albumin excretion at 6 months · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
- Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
Angiotensin‐converting enzyme inhibitors vs placebo
Creatinine level · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
- Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
Angiotensin‐converting enzyme inhibitors vs placebo
Electrolyte levels · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
- Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
Angiotensin‐converting enzyme inhibitors vs placebo
Blood pressure · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
- Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
Angiotensin‐converting enzyme inhibitors vs placebo
Hemoglobin concentration (g/dL) · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
- Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
Angiotensin‐converting enzyme inhibitors vs placebo
Adverse events or toxicity · People with proteinuria or microalbuminuria due to sickle cell disease
1 finding from 1 review
- Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
HFNC vs standard oxygen therapy
Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support
HFNC may leads to lower treatment failure (escalation of respiratory therapy to NIV, NIPPV… compared with standard oxygen therapy (low certainty).
1 finding from 1 review
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyRR 0.62 [0.45, 0.86]15 studies · 3044 participantsLow
HFNC vs NIPPV or NIV
Adverse events ‐ pneumonia · adults in the ICU, requiring respiratory support
It is very uncertain whether HFNC changes adverse events Respiratory infection (pneumonia) compared with NIPPV or NIV (very low certainty).
1 finding from 1 review
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyRR 0.51 [0.17, 1.52]3 studies · 1750 participantsVery low
HFNC vs NIPPV or NIV
Barotrauma (pneumothorax) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in barotrauma (pneumothorax) compared with NIPPV or NIV (low certainty).
1 finding from 1 review
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyRR 1.15 [0.42, 3.14]1 study · 830 participantsLow
HFNC vs NIPPV or NIV
Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
The review found no eligible studies for this question.
1 finding from 1 review
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
HFNC vs NIPPV or NIV
Duration of ICU stay · adults in the ICU, requiring respiratory support
1 finding from 1 review
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 246 participantsLow
HFNC vs NIPPV or NIV
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1086 participantsLow
HFNC vs NIPPV or NIV
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 258 participantsVery low
- High‐flow nasal cannulae for respiratory support in adult intensive care patients 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low